Viatris Raises Guidance as China Surges and Pipeline Delivers: A Turnaround in Motion?

Q2 beat drives guidance hike; strategic pivot away from eye care and strong China performance point to a new growth phase.

VTRS · Earnings Call · 2026-08-06

Viatris: A Turnaround Gains Momentum, but Supply and Policy Risks Loom

Strong Second Quarter and Raised Guidance

Viatris kicked off 2026 with an exceptional first half. “We're off to an exceptional start in 2026.” — Scott Smith, Chief Executive Officer · 2026-08-06 Total revenues for Q2 reached $3.8B, up 3.5% operationally, while adjusted EBITDA hit $1.2B and adjusted EPS came in at $0.69. Management raised the midpoint of all key 2026 guidance ranges, crediting strong commercial execution and the early fruits of the enterprise-wide strategic review. The financial flexibility from a healthy cash flow and monetization of the Biocon stake underpins a balanced capital allocation approach—“we ran ahead of expectations for the first half, both revenue and EBITDA.” — Paul Campbell, Interim Chief Financial Officer · 2026-08-06

The Engine: China and E-commerce

The standout driver remains Greater China, where net sales jumped 16% year-over-year, with e-commerce soaring 36%. “There's a real focus right now in China on health care, quality of life.” — Scott Smith, Chief Executive Officer · 2026-08-06 This momentum is not new—on the prior quarter call, Scott Smith noted that China is the “strongest China market over the last 12, 18 months that I've ever seen.” — Scott Smith, CEO · 2026-05-07 Management expects growth to moderate as a policy change rolls out across hospital channels, but they remain bullish on the durable brand equity and expanding retail and e-commerce footprint.

Pipeline Progress and Strategic Pivot

R&D momentum accelerated with the FDA approval of Gwyn Lo, a once-weekly contraceptive patch, and fast-acting meloxicam is making its way through review with a potential $500M peak sales opportunity (“we could reach up to $500 million in peak sales with this asset” — Corinne Le Goff, Chief Commercial Officer · 2026-08-06). The obesity-adjacent estrogen patch franchise, boosted by the removal of black-box warnings, is seeing estradiol patch demand outpace supply. Advanced programs like selatogrel and cenerimod are on track for readouts in 2027, with selatogrel powered for a ~20% risk reduction and already enrolling 1,200 patients per month. Philippe Martin highlighted the importance of the interferon 1 signature in cenerimod's design, a key differentiator. Meanwhile, the company agreed to divest Tyrvaya, signaling a strategic exit from eye care to focus on higher-growth therapeutic areas.

We're building a stronger company. We're improving the quality of our earnings, strengthening our operating model, sharpening our portfolio and investing behind the opportunities we believe will drive sustainable long-term growth.
Scott Smith, Chief Executive Officer · 2026-08-06

Capital Allocation and Cost Savings

The strategic review is delivering net savings of $400M, with ~$120M expected this year—a key driver of the operating leverage. “We're delivering on that. And from that, we're seeing real EBITDA leverage here for the second quarter in a row.” — Scott Smith, Chief Executive Officer · 2026-08-06 Debt repayments reduced gross leverage to 2.9x, and the company has returned $550M to shareholders via dividends and buybacks. With $1.6B in deployable capital for the remainder of the year, management is positioned to pursue good strength in business development opportunities. The financial flexibility is evident in the balance sheet improvement, with stronger operating income as a percentage of revenue.

Risks and Outlook

Despite the upbeat tone, headwinds persist. The Nashik facility disruption—caused by a fire and FDA inspection—is expected to cost $100–150M in second-half revenues, although management characterizes it as temporary and largely isolated to low-margin generics. Competition is intensifying in developed markets, particularly for Breyna and Wixela, while China's procurement policy introduces uncertainty. Still, the company raised guidance across the board, signaling confidence that the tailwinds from China and the pipeline will more than offset these challenges. The 90-day price tape shows a +21.2% advance, reflecting growing investor conviction in the turnaround narrative.